lee011,ribociclib
novartis
['bcsm', 'ribociclib', 'monaleesa-2']
dose reduction of ribociclib did not impact overall survival in monaleesa-2 trial. #asco22 #bcsm 
Director Breast Oncology, Lifespan Cancer Institute, Legorreta Cancer Center Brown Univ | Medical Advisor @drloveresearch | #bcsm #clinicaltrials | Views Mine